Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?
Kronenwett
R
R
Clinical Cooperation Unit Molecular Hematology/Oncology (460), German Cancer Research Center, Heidelberg, Germany.
Haas
R
R
D000818:Animals; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D051379:Mice; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D016337:RNA, Catalytic / Q000627:therapeutic use*; D018075:RNA, Complementary / Q000032:analysis
D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic; D018075:RNA, Complementary; D016044:Fusion Proteins, bcr-abl